Clinical outcomes with chemotherapy for advanced thymic carcinoma

Lung Cancer

Volumn 80, Issue 1, 2013, Pages 75-80

  Okuma, Yusuke ^a   Hosomi, Yukio ^a   Takagi, Yusuke ^a   Sasaki, Eisaku ^a   Hishima, Tsunekazu ^a   Maeda, Yoshiharu ^a   Shibuya, Masahiko ^a   Okamura, Tatsuru ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Chemotherapy; Metastasis; Prognostic significance; Thymic carcinoma; Thymic epithelial neoplasm

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IRINOTECAN; VINCRISTINE;

ADENOSQUAMOUS CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD REVIEW; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THYMUS CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THYMOMA; THYMUS NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 84875266804     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.012     Document Type: Article

References (35)

1. Engels E.A., Pfeiffer R.M. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003, 105:546-551.
2. Suster S., Rosai J. Histology of the normal thymus. Am J Surg Pathol 1990, 14:284-303.
3. Kuo T. Cytokeratin profiles of the thymus and thymomas: histogenetic correlations and proposal for a histological classification of thymomas. Histopathology 2000, 36:403-414.
4. ITMIG definitions and policies. J Thorac Oncol 2011, 6:S1689-S1755.
5. Weksler B., Dhupar R., Parikh V., Nason K.S., Pennathur A., Ferson P.F. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg 2012.
6. Lemma G.L., Lee J.W., Aisner S.C., Langer C.J., Tester W.J., Johnson D.H., et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011, 29:2060-2065.
7. Suster S., Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991, 67:1025-1032.
8. Rosai J., Sobin L. Histological typing of tumors of the thymus. WHO international histological classification of tumours 1999, Springer-Verlag, Berlin, Heidelberg. 2nd ed.
9. Muller-Hermelink H.K., Marino M., Palestro G. Pathology of thymic epithelial tumors. Curr Top Pathol 1986, 75:207-268.
10. Travis W., Brambilla W., Müller-Hermelink H., Harris C. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, IARC press, Lyon, [Chapter 3].
11. Okumura M., Ohta M., Tateyama H., Nakagawa K., Matsumura A., Maeda H., et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002, 94:624-632.
12. Quintanilla-Martinez L., Wilkins E.W., Choi N., Efird J., Hug E., Harris N.L. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994, 74:606-617.
13. Petrini I., Zucali P.A., Lee H.S., Pineda M.A., Meltzer P.S., Walter-Rodriguez B., et al. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 2010, 5:1447-1453.
14. Nickels J., Franssila K. Thymoma metastasizing to extrathoracic sites. A case report. Acta Pathol Microbiol Scand A 1976, 84:331-334.
15. Kong D.S., Lee J.I., Nam D.H., Park K., Suh Y.L. Cerebral involvement of metastatic thymic carcinoma. J Neurooncol 2005, 75:143-147.
16. Agatsuma T., Koizumi T., Kanda S., Ito M., Urushihata K., Yamamoto H., et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 2011, 6:2130-2134.
17. Yoh K., Goto K., Ishii G., Niho S., Ohmatsu H., Kubota K., et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003, 98:926-931.
18. Igawa S., Murakami H., Takahashi T., Nakamura Y., Tsuya A., Naito T., et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010, 67:194-197.
19. Okuma Y., Hosomi Y., Takagi Y., Iguchi M., Okamura T., Shibuya M. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 2011, 74:492-496.
20. Moran C.A., Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000, 114:100-110.
21. Fornasiero A., Daniele O., Ghiotto C., Piazza M., Fiore-Donati L., Calabro F., et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991, 68:30-33.
22. Loehrer P.J., Kim K., Aisner S.C., Livingston R., Einhorn L.H., Johnson D., et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994, 12:1164-1168.
23. Schmitt J., Loehrer P.J. The role of chemotherapy in advanced thymoma. J Thorac Oncol 2010, 5:S357-S360.
24. Magois E., Guigay J., Blancard P.S., Margery J., Milleron B., Lher P., et al. Multimodal treatment of thymic carcinoma: report of nine cases. Lung Cancer 2008, 59:126-132.
25. Frei E., Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980, 69:585-594.
26. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1983, 1:710-719.
27. Hsu C.H., Yeh K.H., Cheng A.L. Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res 1997, 17:1331-1334.
28. Igawa S., Murakami H., Yamamoto N. Thymic small cell carcinoma shows marked response to amrubicin. J Thorac Oncol 2009, 4:778.
29. Okuma Y., Shimokawa T., Takagi Y., Hosomi Y., Iguchi M., Okamura T., et al. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer 2010, 70:357-363.
30. Oberg K., Kvols L., Caplin M., Delle Fave G., de Herder W., Rindi G., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15:966-973.
31. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350:2625-2626.
32. Li X.F., Chen Q., Huang W.X., Ye Y.B. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009, 26:157-160.
33. Strobel P., Bargou R., Wolff A., Spitzer D., Manegold C., Dimitrakopoulou-Strauss A., et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
34. Schirosi L., Nannini N., Nicoli D., Cavazza A., Valli R., Buti S., et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 2012.
35. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008, 26:3913-3915.